Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI

NCT04856059 · tracked via the Priya Life Science Canada tracker

Sponsor

University Health Network, Toronto

Phase

Not applicable

Started

2021-06-15

Last updated

2026-04-16

Condition(s) studied

Fabry Disease

Investigational drug(s) / intervention(s)

Cardiac MRI, ECG/Holter and Blood Biomarkers

Cardiac MRI, ECG/Holter and Blood Biomarkers: Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up

Study summary

This study will evaluate whether cardiac MRI T1 and T2 mapping improves our ability to detect early abnormalities in the heart in patients with Fabry disease and identify patients at increase risk of adverse events.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Fabry disease; * Age ≥ 18 years. Exclusion Criteria: * History of myocardial infarction; * Contraindication to MRI.

Primary outcome measure(s)

Major Adverse Cardiac Events (MACE) — 5 years
MACE will be assessed as a composite endpoint defined by the development on one or more of events such as sustained ventricular tachycardia (VT), severe bradycardia, heart failure hospitalization and cardiac death.

Trial sites (1)

Facility	City	Region	Status
University Health Network	Toronto	Ontario	Recruiting

More University Health Network, Toronto trials in Canada

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis Recruiting

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy Active, not recruiting

CBF and NCF Changes With Brain Radiation Active, not recruiting

A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T Recruiting

Outcomes Post Treatment: Impact on Motor Impairment of Sleep Efficiency in SCI (OPTIMISE SCI Trial) Recruiting

Other trials for the same condition

Fabry Disease Registry & Pregnancy Sub-registry Recruiting

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease Active, not recruiting

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease Active, not recruiting

Canadian Fabry Disease Initiative (CFDI) National Registry Recruiting

A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry Disease Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04856059 on ClinicalTrials.gov ↗ ← All trials in Canada